Roman Fleck, PhD
Chief Executive Officer
Roman is the CEO of Janpix, Ltd., as well as a Venture Advisor to Medicxi (formerly Index Ventures Life Sciences). Previously, he was a Principal at Index Ventures where among others he invested in and represented Index Ventures on the boards of GlycoVaxyn (sold to GSK), Versartis (NASDQ: VSAS), and Novocure (NASDQ: NVCR). Earlier at Index Ventures he was also involved with Funxional Therapeutics (sold to Boehringer Ingelheim) and Micromet (sold to Amgen). He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he led drug development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage. Roman received a PhD in bioorganic chemistry from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as many issued patents.
Patrick T Gunning, PhD
Chief Scientific Officer
Patrick T. Gunning is a full Professor of chemistry and Canada research Chair in Medicinal Chemistry at the Department of Chemical and Physical Sciences, University of Toronto Mississauga. Dr. Gunning’s research has focused on the development of small molecule inhibitors of protein-protein interactions, namely disruptors of STAT3 and STAT5 proteins. In this field, Dr. Gunning has authored or coauthored 89 research publications and received numerous awards and honours. These include the 2015 Rose Winer Levin Lectureship by Dana-Farber Cancer Institute and Harvard Medical School, the 2012 RSC MedChemComm Emerging Investigator Lectureship by the Royal Society for Chemistry (UK), the 2016 Canadian Society for Chemistry’s Bernard Belleau award and named in Canada’s Top 40 under 40 awardees.
Kay Noel, PhD
VP Preclinical Development
Dr. Noel has over 30 years experience in pharmaceutical development, with 10 NDA approvals. She has extensive experience in portfolio development, in-licensing, and out-licensing. Currently, she also serves as Chief Operating Officer of Collaborative Medicinal Development LLC, a private company specializing in development of novel compounds for treatment of neurodegenerative diseases and cancer, with four ongoing clinical trials. Previous successful start-up and product development experiences include creation of the first healthcare business plan, managing a $75 million financing, and development and marketing of the first PCR kits at Cetus Corporation; co-founding and serving as Vice President, Commercial Development for a novel oncology drug distribution system called Oncology Therapeutics Network, subsequently sold to Bristol Myers Squibb; and co-founding and serving as Chief Operating Officer for OncoEthix SA, a cancer drug development company, subsequently sold to Merck. Dr. Noel has a PhD in biophysics from the University of Michigan (Ann Arbor, MI).
Giovanni is a Prinicipal in the Medicxi investment team with main focus on growth stage clinical opportunities. Prior to joining Medicxi, Giovanni was a Principal with Index Ventures, having joined the firm in 2012. Before that he was at Cancer Research UK's London Research Institute (LRI; now the Crick Institute). At the LRI he conducted research focused on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects to biopharmaceutical companies in the oncology field. Giovanni currently sits on the board of directors of Gadeta, SuperX Pharma, Kymo Therapeutics and Janpix. He obtained a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.
Francesco De Rubertis
Francesco De Rubertis is Partner and co-founder of Medicxi. Prior to this, he was with Index Ventures for 18 years, having joined the firm in 1997 to launch its life sciences practice. While at Index life sciences, he spearheaded the creation and adoption of the asset-centric investment strategy and led the growth of the firm. At Medicxi he also oversees the firm’s operations. Francesco’s investments include CellZome (acquired by GlaxoSmithKline), Egalet (NASDAQ: EGLT), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, NASDAQ: AFFX), Profibrix (acquired by The Medicines Company), Versartis (NASDAQ: VSAR) and several others. Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral scientist at the Whitehead Institute at MIT. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva.
Scientific Advisory Board
To be disclosed.